Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity

被引：0
|
作者：
Jasmin Bartl
Thomas Müller
Edna Grünblatt
Manfred Gerlach
Peter Riederer
机构：
[1] University of Zurich,Hospital of Child and Adolescent Psychiatry
[2] St. Joseph Hospital Berlin-Weissensee,Department of Neurology
[3] University of Zurich and ETH Zurich,Neuroscience Center Zurich
[4] University Hospital of Wuerzburg,Department of Psychiatry, Psychosomatics and Psychotherapy
[5] University of Wuerzburg,Department of Child and Adolescents Psychiatry, Psychosomatics and Psychotherapy
[6] Institute Cognitive Brain Sciences,undefined
[7] NCGG,undefined
[8] University Hospital of Wuerzburg,undefined
[9] University of Wuerzburg,undefined
来源：
Journal of Neural Transmission | 2014年 / 121卷
关键词：
Parkinson’s disease; MAO-A; MAO-B inhibitors; Selegiline; Rasagiline;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily.
引用
收藏
页码：379 / 383
页数：4
相关论文
共 50 条
12345